Prospective study of vinorelbine and capecitabine combination therapy in chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes

Chemotherapy

Volumn 56, Issue 4, 2010, Pages 340-347

  Fan, Ying ^a   Xu, Binghe ^a   Yuan, Peng ^a   Wang, Jiayu ^a   Ma, Fei ^a   Li, Qing ^a   Zhang, Pin ^a   Li, Qiao ^a   Cai, Ruigang ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Anthracycline pretreated; Breast neoplasms; Capecitabine; Combination chemotherapy; Taxane pretreated; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CHINESE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; REMISSION INDUCTION; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; YOUNG ADULT;

EID: 77955602244     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320186     Document Type: Article

References (38)

1. Ries LAG, Melbert D, Krapcho M, Mariotto A, et al: SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. http://seer.cancer.gov/csr/1975- 2004 (accessed April 17, 2008).
2. Weber BL, Vogel C, Jones S, Harvey H, et al: Intravenous vinorelbine as first-line and second- line therapy in advanced breast cancer. J Clin Oncol 1995; 13: 2722-2730.
3. Budman DR: Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest 1997; 15: 475-490.
4. Johnson SA, Harper P, Hortobagyi GN, Pouillart P: Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127-142.
5. Fumoleau P, Largillier R, Clippe C, Dièras V, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536-542.
6. Thomas ES, Gomez HL, Li RK, Chung HC, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
7. Blum JL, Jones SE, Buzdar AU, LoRusso PM, et al: Multicenter phase II study of capeci - ta bine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493.
8. Abeloff MD: Vinorelbine (Navelbine) in the treatment of breast cancer: a summary. Semin Oncol 1995; 22(suppl 5):1-4.
9. Bissery MC, Vrignaud P, Lavelle F: Preclinical profile of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol 1995; 22(suppl 13):3-16.
10. Zelek L, Barthier S, Riofrio M, Fizazi K, et al: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast cancer. Cancer 2001; 92: 2267-2272.
11. Fumoleau P, Largillier R, Clippe C, Dièras V, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40: 536-542.
12. Blum JL, Dieras V, Lo Russo PM, Horton J, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92: 1759-1768.
13. Seidman AD, O'Shaughnessy J, Misset JL: Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7(suppl 6):20-28.
14. Reichardt P, von Minckwitz G, Thuss-Patience PC, Jonat W, et al: Multicenter phase II study of oral capecitabine (Xeloda-) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14: 1227-1233.
15. Thomas ES, Gomez HL, Li RK, Chung HC, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
16. Geyer CE, Forster J, Lindquist D, Chan S, et al: Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
17. Sawada N, Ishikawa T, Fukase Y, Nishida M, et al: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013-1019.
18. Oksuzoglu B, Abali H, Hayran M, Yildirim N, et al: Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. Chemotherapy 2008; 54: 352-356.
19. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline pretreated patients with metastatic breast cancer: phase II trial results. J Clin Oncol 2002; 20: 2812-2823.
20. Dieras V, Extra JM, Bellissant E, Espie M, et al: Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 1996; 14: 3097-3104.
21. Zambetti M, Demicheli R, De Candis D, Antonelli G, et al: Five day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 1997; 44: 255-260.
22. Froudarakis ME, Catimel G, Guastalla JP, Rebattu P, et al: Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma. Oncology 1998; 55: 87-88.
23. Sawada N, Fujimoto-Ouchi F, Ishikawa T, Ishiguro T, et al: Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002; 43: 1088 (abstr 5388).
24. DCTD, NCI, NIH, DHHS: Common Toxicity Criteria, version 2.0. 1998. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf (accessed August 21, 2009).
25. Somali I, Alacacioglu A, Tarhan MO, Meydan N, et al: Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. Chemotherapy 2009; 55: 155-160.
26. Welt A, von Minckwitz G, Oberhoff C, Borquez D, et al: Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005; 16: 64-69.
27. Lorusso V, Crucitta E, Silvestris N, Guida M, et al: A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer 2003; 4: 138-141.
28. Ghosn M, Kattan J, Farhat F, Younes F, et al: Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 2006; 26: 2451-2456.
29. Ahn JH, Kim SB, Kim TW, Ahn SH, et al: Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004; 19: 547-553.
30. Estévez LG, Batista N, Sánchez-Rovira P, Velasco A, et al: A phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 2008; 8: 149-154.
31. Hess D, Koberle D, Thurlimann B, Pagani O, et al: Swiss Group for Clinical Cancer Research. Capecitabine and vinorelbine as first-line treatment in elderly patients ( 1 or = 65 years) with metastatic breast cancer: a phase II trial (SAKK 25/99). Oncology 2007; 73: 228-237.
32. Hess D, Thürlimann B, Pagani O, Aebi S, et al: Capecitabine and vinorelbine in elderly patients ( 1 or = 65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004; 15: 1760-1765.
33. Koizumi W, Okayasu I, Hyodo I, Sakamoto J, et al: Prediction of the effect of capecit abine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs 2008; 19: 819-824.
34. Salgado J, Zabalegui N, Gil C, Monreal I, et al: Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer. Oncol Rep 2007; 17: 325-328.
35. Berrieman HK, Cawkwell L, O'Kane SL, Smith L, et al: Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer. Oncol Rep 2006; 15: 283-286.
36. Colleoni M, Orvieto E, Nolé F, Orlando L, et al: Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999; 35: 574-579.
37. Finek J, Holubec L Jr, Svoboda T, Sefrhansova L, et al: A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009; 29: 667-670.
38. Lorusso V, Spada M, Giampaglia M, Misino A, et al: Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC): A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). Ann Oncol 2006; 17(suppl 7):vii15-vii17.